Meeting
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
Authors
Thomas Powles
Barts Cancer Centre, Queen Mary University of London, London, United Kingdom
Thomas Powles , Joshua J Meeks , Matt D. Galsky , Michiel Simon Van Der Heijden , Hiroyuki Nishiyama , Hikmat A Al-Ahmadie , Erik T. Goluboff , Stephan Hois , Sarah E. Donegan , Vanessa Williams , Feng Xiao , James WF Catto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03732677
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr TPS505)
DOI
10.1200/JCO.2021.39.6_suppl.TPS505
Abstract #
TPS505
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).
First Author: Thomas Powles
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).
First Author: Thomas Powles
Poster
2023 ASCO Annual Meeting
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
First Author: Tianxin Lin
Poster
2022 ASCO Annual Meeting
ANTICIPATE: A phase I/II, open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC).
First Author: Matt D. Galsky